Search Results - "KNAPPERTZ, V"

Survival in MS: A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial by GOODIN, D. S, REDER, A. T, KNAPPERTZ, V, EBERS, G. C, CUTTER, G, KREMENCHUTZKY, M, OGER, J, LANGDON, D, RAMETTA, M, BECKMANN, K, DESIMONE, T. M

“…To examine the effects of interferon beta (IFNβ)-1b on all-cause mortality over 21 years in the cohort of 372 patients who participated in the pivotal…”
Get full text

Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis by Croze, E, Yamaguchi, K D, Knappertz, V, Reder, A T, Salamon, H

“…Interferon beta (IFNβ) reduces disease burden in relapsing-remitting multiple sclerosis (MS) patients. In this study, IFNβ-1b-treated MS patient gene…”
Get full text

Interferon beta -1b-neutralizing antibodies 5 years after clinically isolated syndrome by Hartung, H-P, Freedman, MS, Polman, CH, Edan, G, Kappos, L, Miller, D H, Montalban, X, Barkhof, F, Petkau, J, White, R, Sahajpal, V, Knappertz, V, Beckmann, K, Lanius, V

“…Objective: To determine the frequency and consequences of neutralizing antibodies (NAbs) in patients with a first event suggestive of multiple sclerosis (MS)…”
Get full text

Interferon β-1b―neutralizing antibodies 5 years after clinically isolated syndrome by HARTUNG, H.-P, FREEDMAN, M. S, SAHAJPAL, V, KNAPPERTZ, V, BECKMANN, K, LANIUS, V, SANDBRINK, R, POHL, C, POLMAN, C. H, EDAN, G, KAPPOS, L, MILLER, D. H, MONTALBAN, X, BARKHOF, F, PETKAU, J, WHITE, R

“…To determine the frequency and consequences of neutralizing antibodies (NAbs) in patients with a first event suggestive of multiple sclerosis (MS) treated with…”
Get full text

Interferon β-1b and glatiramer acetate effects on permanent black hole evolution by Filippi, M, Rocca, M A, Camesasca, F, Cook, S, O'Connor, P, Arnason, B G W, Kappos, L, Goodin, D, Jeffery, D, Hartung, H-P, Comi, G, Wolinsky, J S, Bogumil, T, Pohl, C, Beckmann, K, Sandbrink, R, Croze, E, Brown, C, Desimone, T M, Arnold, D L, Cutter, G, Knappertz, V

“…To compare interferon β-1b (IFNβ-1b) and glatiramer acetate (GA) on new lesion (NL) (gadolinium-enhancing, new T2) evolution into permanent black holes…”
Get full text

Survival in commercially insured multiple sclerosis patients and comparator subjects in the U.S by Kaufman, D.W, Reshef, S, Golub, H.L, Peucker, M, Corwin, M.J, Goodin, D.S, Knappertz, V, Pleimes, D, Cutter, G

“…Abstract Objective Compare survival in patients with multiple sclerosis (MS) from a U.S. commercial health insurance database with a matched cohort of non-MS…”
Get full text

Effects of inhibitors of the renin-angiotensin system on the efficacy of interferon beta-1b: a post hoc analysis of the BEYOND study by Doerner, M, Beckmann, K, Knappertz, V, Kappos, L, Hartung, H P, Filippi, M, O'Connor, P W, Arnason, B, Cook, S, Jeffery, D, Comi, G, Limmroth, V

“…In experimental autoimmune encephalomyelitis, inhibition of the renin-angiotensin system with angiotensin receptor blockers (ARBs) or angiotensin-converting…”
Get more information

Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing–remitting multiple sclerosis by Acaster, S, Swinburn, P, Wang, C, Stemper, B, Beckmann, K, Knappertz, V, Pohl, C, Sandbrink, R, Gondek, K, Edan, G, Kappos, L, Freedman, M, Hartung, H-P, Arnason, B, Comi, G, Filippi, M, Jeffery, D, O’Connor, P, Cook, S, Lloyd, AJ

“…Background: The Functional Assessment of Multiple Sclerosis (FAMS) is widely used in clinical trial programmes; however, it was developed before the rise in…”
Get full text

Lack of hemispheric dominance for consciousness in acute ischaemic stroke by Cucchiara, B, Kasner, S E, Wolk, D A, Lyden, P D, Knappertz, V A, Ashwood, T, Odergren, T, Nordlund, A

“…Background: Previous reports have suggested left hemispheric dominance for maintaining consciousness, although there is controversy over this claim. Objective:…”
Get full text

FP39-WE-01 Long-term follow-up 20 years after the pivotal interferon beta-1b multiple sclerosis trial by Goodin, D.S, Ebers, G, Cutter, G, Traboulsee, A, Langdon, D, Reder, A.T, Rametta, M, Knappertz, V

Get full text

Vagus nerve imaging with ultrasound: Anatomic and in vivo validation by Knappertz, Volker A., Tegeler, Charles H., Hardin, Sharon J., McKinney, William M.

“…To provide the anatomic basis and demonstrate the reproducibility of ultrasound studies for the identification of the vagus nerve within its course in the…”
Get full text

Cough headache and the competency of jugular venous valves by Knappertz, V A

Get full text

Carotid Doppler high-intensity transient signals in dilated cardiomyopathy by Knappertz, Volker A., Tegeler, Charles H., Furberg, Curt D., Wesley, Deborah J., Stewart, Kathryn P., Kitzman, Dalane W.

“…Background Thromboembolism is an infrequent but serious complication in dilated cardiomyopathy (DCM), and the role of primary preventive antithrombotic or…”
Get full text

Transcranial Doppler sonography in dementia of Alzheimer type by Heun, R, Knappertz, V, Kraemer, G

“…The intention of this study was to examine the relation of clinical variables and cognitive dysfunction to cerebrovascular blood flow in a sample of patients…”
Get more information

Mortality in Multiple Sclerosis in the United States (MIMS-US): A Retrospective, Cohort Study of Survival and Mortality Trends (P06.195) by Reshef, S., Cutter, G., Golub, H., Brueckner, A., Knappertz, V.

“…Abstract only…”
Get full text

Multiple Sclerosis Patients Treated with IFNB-1b Express a Unique Isoform of the Oxidation Resistance Protein NCOA7 (P02.073) by Yu, L., Croze, E., Knappertz, V., Volkert, M.

“…Abstract only…”
Get full text

Middle cerebral artery velocity correlates with nitroglycerin-induced headache onset by Tegeler, C H, Davidai, G, Gengo, F M, Knappertz, V A, Troost, B T, Gabriel, H, Davis, R L

“…Headache often accompanies treatment with nitroglycerin, but the cerebral hemodynamic effects and the exact mechanism of the headache are incompletely…”
Get more information

Clinical Outcomes and Cause of Death for Interferon Beta-1b Versus Placebo, 21 Years Following Randomization (P04.129) by Reder, A., Goodin, D., Ebers, G., Cutter, G., Kremenchutzky, M., Oger, J., Langdon, D., Rametta, M., Beckmann, K., Knappertz, V.

“…Abstract only…”
Get full text

Aktuelle Entwicklungen in der klinischen Interferon-β-1b-Forschung by Knappertz, V.

Get full text

Survival in MS by Goodin, D S, Reder, A T, Ebers, G C, Cutter, G, Kremenchutzky, M, Oger, J, Langdon, D, Rametta, M, Beckmann, K, DeSimone, T M, Knappertz, V

“…Objective: To examine the effects of interferon beta (IFN beta )-1b on all-cause mortality over 21 years in the cohort of 372 patients who participated in the…”
Get full text